Dirksen E. Bussiere
Novartis (Switzerland)(CH)Novartis (China)(CN)Novartis Institutes for BioMedical Research
Publications by Year
Research Areas
DNA Repair Mechanisms, Bacterial Genetics and Biotechnology, Crystallization and Solubility Studies, Cancer-related gene regulation, RNA and protein synthesis mechanisms
Most-Cited Works
- → Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo(2014)724 cited
- → Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase(2011)487 cited
- → Harnessing the anti-cancer natural product nimbolide for targeted protein degradation(2019)412 cited
- → Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer(2011)249 cited
- → Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex(2019)249 cited
- → Discovery and Development of GSK3 Inhibitors for the Treatment of Type 2 Diabetes(2004)157 cited